Technical Analysis for CELC - Celcuity Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 17.70 | -0.78% | -0.14 |
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | -0.78% | |
| MACD Bullish Signal Line Cross | Bullish | -0.78% | |
| NR7 | Range Contraction | -0.78% | |
| Narrow Range Bar | Range Contraction | -0.78% | |
| Stochastic Reached Overbought | Strength | -0.78% | |
| Inside Day | Range Contraction | -0.78% | |
| Overbought Stochastic | Strength | -0.78% | |
| Up 3 Days in a Row | Strength | -0.78% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 7 hours ago |
| Up 1% | about 10 hours ago |
| 50 DMA Support | about 11 hours ago |
| 60 Minute Opening Range Breakout | about 11 hours ago |
| Down 1% | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/13/2024
Celcuity Inc. Description
Celcuity, Inc. is a United States-based early stage biotechnology company. The Company develops tests that functionally analyze diseased live cells. The Company has developed CELx Pathway Profile technology, which combines advancements in primary tissue research with a method of measuring a targeted therapy's functional pathway effect on live and diseased patient cells. The Company offers functional cellular analysis platform that assesses the functionality of the disease-related signaling pathways of patient's diseased cells ex vivo and determines whether a drug therapy has the effect on diseased cells. The Company's CELx test is designed to determine whether a pathway is functional to therapeutic intervention without regard to the exact mechanism a patient's tumor may have developed to resist the therapeutic effect. The Company’s diagnostic approach helps to identify cancer subtypes.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biotechnology Cancer Biology Stem Cell Cell Biology Signal Transduction Targeted Therapy Systems Biology Cell Signaling Drug Therapy Patient's Tumor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.188 |
| 52 Week Low | 8.389 |
| Average Volume | 263,420 |
| 200-Day Moving Average | 13.50 |
| 50-Day Moving Average | 17.90 |
| 20-Day Moving Average | 17.29 |
| 10-Day Moving Average | 16.76 |
| Average True Range | 0.89 |
| RSI (14) | 52.15 |
| ADX | 17.17 |
| +DI | 28.70 |
| -DI | 26.52 |
| Chandelier Exit (Long, 3 ATRs) | 17.49 |
| Chandelier Exit (Short, 3 ATRs) | 17.29 |
| Upper Bollinger Bands | 19.42 |
| Lower Bollinger Band | 15.16 |
| Percent B (%b) | 0.6 |
| BandWidth | 24.63 |
| MACD Line | -0.22 |
| MACD Signal Line | -0.34 |
| MACD Histogram | 0.1118 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 18.54 | ||||
| Resistance 3 (R3) | 18.60 | 18.37 | 18.40 | ||
| Resistance 2 (R2) | 18.37 | 18.16 | 18.35 | 18.35 | |
| Resistance 1 (R1) | 18.04 | 18.03 | 17.93 | 17.98 | 18.31 |
| Pivot Point | 17.81 | 17.81 | 17.76 | 17.79 | 17.81 |
| Support 1 (S1) | 17.48 | 17.60 | 17.37 | 17.42 | 17.09 |
| Support 2 (S2) | 17.25 | 17.47 | 17.23 | 17.05 | |
| Support 3 (S3) | 16.92 | 17.25 | 17.00 | ||
| Support 4 (S4) | 16.86 |
